IDH1 and central nervous system cancer: These data support the rationale that stratifying gliomas by IDH1 mutation status enables more precisely targeted immunotherapeutics, such as checkpoint inhibitors and improved outcomes for patients with chemo/radiotherapy-resistant wildtype IDH1 gliomas.